Adiposity and Alzheimer's disease

被引:51
作者
Luchsinger, Jose A.
Mayeux, Richard
机构
[1] Columbia Univ, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY 10027 USA
[2] Columbia Univ, Gertrude H Sergievsky Ctr, New York, NY 10027 USA
[3] Columbia Univ, Dept Med, Div Gen Med, Coll Phys & Surg, New York, NY 10027 USA
[4] Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY 10027 USA
[5] Columbia Univ, Joseph P Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10027 USA
[6] Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY 10027 USA
关键词
D O I
10.2174/156720507780362100
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The objective of this manuscript is to provide a comprehensive review of the relation between adiposity and Alzheimer's disease (AD), its potential mechanisms, and issues in its study. Adiposity represents the body fat tissue content. When the degree of adiposity increases it can be defined as being overweight or obese by measures such as the body mass index. Being overweight or obese is a cause of hyperinsulinernia and diabetes, both of which are risk factors for AD. However, the epidemiologic evidence linking the degree of adiposity and AD is conflicting. Traditional adiposity measures such as body mass index have decreased validity in the elderly. Increased adiposity in early or middle adult life leads to hyperinsulinemia which may lead to diabetes later in life. Thus, the timing of ascertainment of adiposity and its related factors is critical in understanding how it might fit into the pathogenesis of AD. We believe that the most plausible mechanism relating adiposity to AD is hyperinsulinemia, but it is unclear whether specific products of adipose tissue also have a role. Being overweight or obese is increasing in children and adults, thus understanding the association between adiposity and AD has important public health implications.
引用
收藏
页码:127 / 134
页数:8
相关论文
共 79 条
[1]   Lilly Lecture, 2003 - The struggle for mastery in insulin action: From triumvirate to republic [J].
Accili, D .
DIABETES, 2004, 53 (07) :1633-1642
[2]  
Allison DB, 1997, AM J EPIDEMIOL, V146, P339, DOI 10.1093/oxfordjournals.aje.a009275
[3]  
Grundy Scott M, 2005, Crit Pathw Cardiol, V4, P198
[4]   SYNDROMES OF CARDIAC CACHEXIA AND THE CACHECTIC HEART - CURRENT PERSPECTIVE [J].
ANSARI, A .
PROGRESS IN CARDIOVASCULAR DISEASES, 1987, 30 (01) :45-60
[5]   HUMAN-BODY COMPOSITION AND THE EPIDEMIOLOGY OF CHRONIC DISEASE [J].
BAUMGARTNER, RN ;
HEYMSFIELD, SB ;
ROCHE, AF .
OBESITY RESEARCH, 1995, 3 (01) :73-95
[6]   Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset [J].
Brookmeyer, R ;
Gray, S ;
Kawas, C .
AMERICAN JOURNAL OF PUBLIC HEALTH, 1998, 88 (09) :1337-1342
[7]   Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].
Chobanian, AV ;
Bakris, GL ;
Black, HR ;
Cushman, WC ;
Green, LA ;
Izzo, JL ;
Jones, DW ;
Materson, BJ ;
Oparil, S ;
Wright, JT ;
Roccella, EJ .
HYPERTENSION, 2003, 42 (06) :1206-1252
[8]   Diabetes guideline: A summary and comparison of the recommendations of the American Diabetes Association, Veterans Health Administration, and American Association of Clinical Endocrinologists [J].
Clark, MJ ;
Sterrett, JJ ;
Carson, DS .
CLINICAL THERAPEUTICS, 2000, 22 (08) :899-910
[9]   Drug therapy - Alzheimer's disease [J].
Cummings, JL .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (01) :56-67
[10]   Pharmacologic therapy for type 2 diabetes mellitus [J].
DeFronzo, RA .
ANNALS OF INTERNAL MEDICINE, 2000, 133 (01) :73-74